New drug cocktail takes on advanced lung cancer in first human trial
NCT ID NCT07229599
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called MHB036C combined with other anti-cancer medicines in 300 people with advanced lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have tried standard treatments without success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MHB036C (an experimental drug) combined with MHB039A, furmonertinib, or carboplatin
- What this could lead to
- If it works, this could point toward a new treatment option for advanced lung cancer patients who have run out of standard therapies.
- What could go wrong
- This is an early first-in-human trial, so safety and effectiveness are not yet known. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug deliver a toxic payload directly to cancer cells?
- New support model aims to ease burden on caregivers of older lung cancer patients
- Breath of discovery: simple test may sniff out lung cancer
- Personalized T-Cell therapy takes on advanced lung cancer
- Inhaled mRNA therapy takes on solid tumors in first human trial
- New drug combo shows promise for tough lung cancer